Although the presence of anti-DNA antibody is a hallmark of systemic lupus erythematosus (SLE), neither the subsets of B cells that secrete anti-DNA antibody nor the stimuli responsible for the induction of anti-DNA secretion is known. In particular, the role of CD5+ B cells in human SLE, a distinct subpopulation of antibody-secreting cells shown previously to be a source of anti-DNA antibody in murine models of SLE, is unknown. To approach these questions, we developed a sensitive enzyme-linked immunospot (ELIspot) assay to measure spontaneous secretion of antibody to single-stranded (ss) DNA, double-stranded (ds) DNA, tetanus toxoid, and polyclonal immunoglobulin (Ig) by purified CD5+ and CD5-B cells of 15 SLE patients and 15 healthy control subjects. The B cells of only 1 of 15 healthy subjects secreted a significant level of anti-ssDNA antibody, and none secreted antidsDNA. By contrast, in the majority of SLE patients both CD5+ and CD5-B cells secreted IgG and/or IgM anti-ssDNA as well as anti-dsDNA antibody. Further analysis of the antissDNA response revealed that the level of IgG and IgM anti-DNA antibody secretion by CD5-B cells correlated closely with the level of polyclonal Ig production by the same subpopulation (r = 0.81 and 0.70, respectively). In contrast, production of anti-DNA by CD5+ B cells occurred independently of polyclonal Ig production by both CD5+ 
Introduction
Systemic lupus erythematosus (SLE)' is a multisystem disease of unknown etiology characterized by aberrant immune regulation and excessive production of multiple autoantibodies (1) (2) (3) (4) (5) (6) (7) (8) . In spite of extensive studies of both SLE patients and mouse models of lupus-like disease, considerable controversy remains as to whether excess autoantibody production reflects specific stimulation of autoreactive clones (as in a response to specific and/or cross-reactive antigen) (3, 9) or polyclonal activation of many different B cells (10) (11) (12) . The model of selective B cell activation is supported by several findings: (a) there is a disproportionate increase in the concentration of antibodies to a few selected autoantigens in the sera of most autoimmune patients and mice (13, 14) ; (b) B cells capable of autoantibody production selectively and rapidly expand when transferred from autoimmune mice to B cell-depleted recipient mice (15) ; and (c) most of the antibody responses in a chronic graft-versus-host Fl model of SLE are not random but, rather, specific to the autoantigens present at the initiation of the disease (16) . However, numerous lines of evidence also support an etiologic role for polyclonal B cell activation in SLE. For example, (a) B cell hyperresponsiveness and spontaneous polyclonal activation are invariably present in both SLE patients and animal models ofSLE (1, 19-2 1); (b) activation of B cells, in vitro or in vivo, with polyclonal stimulators results in production of a variety of autoantibodies similar to those found in SLE (22, 23) ; (c) chronic polyclonal activation in genetically nonautoimmune mice can cause autoimmune disease (24) ; and (d) genetic studies indicate an intrinsic B cell abnormality in several autoimmune strains of mice that is linked to polyclonal B cell hyperactivity (1, 25) .
The recent discovery that most autoantibodies produced by mice with genetically determined autoimmune disease are derived from B cells expressing the CD5 (Ly 1) antigen (17, 18) offers an exciting new avenue for investigation into the pathogenesis of human autoimmune disease. CD5+ B cells have been found in high numbers in fetal spleen, chronic lymphocytic leukemia, recipients of bone marrow allografts, and patients with rheumatoid arthritis. A variety of studies suggest that human CD5+ B cells constitute a distinct B cell lineage, homologous functionally and phenotypically to mouse Lyl+ B cells (26) (27) (28) (29) (30) (31) (32) (33) (34) . Moreover, upon in vitro stimulation with polyclonal activators, CD5+ B cells produce autoantibodies similar to those seen in rheumatoid arthritis and SLE (27, 28) .
Despite these provocative findings, a role for CD5+ B cells in the production of anti-DNA antibody in SLE has not yet been demonstrated. In an effort to explore this question, we used a sensitive assay to measure the spontaneous production of anti-DNA antibody by CD5+ and CD5-B cells obtained from patients with SLE. The results indicate that both CD5+ and CD5-B cells produce anti-DNA antibody. However, CD5-B cells appear to produce anti-DNA as a consequence ofpolyclonal activation, in vivo, whereas CD5+ B cells do not. (35) . The mean age (±SD) of these patients was 33.7±10.7 yr (range 19-56 yr) (Table I) . Disease activity was assessed at the time ofphlebotomy on the basis of clinical and laboratory findings (fever, arthralgias, rash, oral ulcers or alopecia, elevated erythrocyte sedimentation rate (> 30 mm/h), leukopenia (< 4,000/,ul), hypoalbuminemia (< 3.5 g/dl), hypocomplementemia (CH5e < 20 U/ml), and presence of antinuclear antibody (titer > 1:80) (36 (42) (43) (44) (45) . To calculate the number ofantigen-specific spots, the number of spots on antigen uncoated control wells were subtracted from the number on antigen-coated wells. Statistical methods. Statistical significance was ascertained by the Student's t test and linear regression analysis. Probability values of > 5% were considered not significant.
Results
Characterization ofthe ELIspot assay. Attempts to apply conventional anti-DNA ELISA (46) for measurement of spontaneous anti-DNA secretion were unsatisfactory due to inadequate sensitivity (data not shown). Therefore, we adapted the ELIspot technique, which detects individual antibody secreting cells rather than secreted antibody. The sensitivity and specificity of this assay have been documented in murine (42, 43) as well as human (44, 45) systems, and further characterized and confirmed for the antigens studied herein. If antigen or anti-Ig antibody was not coated onto the plate, spots (indicating antibody secretion) did not develop even in the presence of B cells (data not shown). In the presence of antigen, the ELIspot assay was highly specific as shown in competitive inhibition experiments ( unaffected by IgG but was inhibited by IgM dent manner (Fig. 1 a) In addition to the studies of anti-single stranded (ss) DNA ibjects produced antibody production, in six patients we also studied spontane-:412). A higher ous anti-double stranded (ds) DNA antibody production. As patients sponta-shown in Fig. 4 , the CD5-B cells from all six patients spontanormal controls neously secreted IgG anti-dsDNA. In four of these patients x, 9,767±2,076; both the CD5+ and CD5-B cells produced IgM as well as IgG 9,680+1,984). anti-dsDNA antibody. As shown in the same figure, the CD5+ (Fig. 3, c and d) ducing cells of the CD5-B cell subset in SLE patients. These average values are similar to those previously reported for lupus-prone mice (12) , in which the proportion of B cells producing anti-DNA antibody, as a percentage oftotal Ig secreting cells, was 0.76% to 1.81% in various lupus-prone murine strains. However, in certain of our patients, anti-DNA antibody secreting cells constituted more than 5% of total Ig secreting cells (Fig. 5) .
When individual patients were analyzed with respect to their cellular source of anti-ssDNA antibodies, four patterns were discernible (Table II) : (a) patients whose CD5+ and CD5-B cells both produce anti-DNA antibody, (b) patients who lack circulating anti-DNA antibody producing cells of either type, (c) patients whose CD5-but not CD5+ B cells produce anti-DNA, and (d) patients in whom CD5+ but not CD5-B cells produce anti-DNA. Although the first of these patterns was the most common (n = 7) and was associated with the highest levels of anti-DNA secreting cells, there were three patients whose CD5+ cells alone secreted anti-DNA, and another three patients whose CD5-cells alone secreted anti-DNA. These results suggest that the cellular origin of anti-DNA antibody is heterogeneous with respect to cell lineage (CD5+ vs. CD5-).
Drugs taken by SLE patients at the time of study, particularly corticosteroids, might have affected our results. However, there was no correlation between the level or the B cell source of anti-DNA and corticosteroid use in our patient cohort (Table I) . Among those patients whose CD5+ and CD5-B cells both secreted anti-DNA, one was receiving 40 both SLE patients and healthy control subjects produced IgM anti-DNA antibody upon stimulation with SAC I, IgG anti-DNA antibody was produced only by the B cells of SLE patients. These results further support the notion that in human SLE both types of B cells produce anti-DNA antibody. Relationship ofspontaneous anti-DNA antibody production and polyclonal Ig production in SLE CD5+ and CD5-B cell subpopulations. In order to more directly examine the possible role of polyclonal B cell activation in the production of anti-DNA antibody in SLE, we next examined the relationship between spontaneous polyclonal Ig production and spontaneous anti-ssDNA antibody production for each B cell subpopulation. As shown in Fig. 7 , a and c, anti-DNA antibody production by CD5+ B cells occurred independently ofpolyclonal Ig production. Thus, some patients had very few anti-DNAsecreting CD5+ B cells despite large numbers oftotal (polyclonal) Ig secreting CD5+ B cells, whereas other patients with large numbers of anti-DNA producing CD5+ B cells had a relatively low number of polyclonal Ig secreting CD5+ B cells. This suggests that activation of anti-DNA antibody secreting CD5+ clones, in vivo, does not necessarily depend on polyclonal stimuli. In contrast to these findings, examination ofthe Ig secretion pattern of CD5-B cells reveals a strong correlation between polyclonal Ig production and anti-DNA antibody production (Fig. 7, b and d) , suggesting that anti-DNA antibody producing clones within the CD5-subpopulation were activated, in vivo, by polyclonal stimuli.
IgM anti-TT antibody production by CD5-B cells was also associated with polyclonal IgM production by the same cells (Fig. 7 e) . IgG anti-TT antibody was not associated with polyclonal IgG production; however, IgG anti-TT antibody was produced in very low frequency by only two patients (Fig.  7f) . (17, 18) . The differences may reflect the lymphooduction and polyclonal cyte sources examined; peripheral blood was analyzed in the Isubpopulation, (b) those present study, whereas spleen cells have been the major cell (c) IgG anti-ssDNA antisource studied in lupus mice. Alternatively, the mechanism wE CD5-B cell subpopula-responsible for anti-DNA production in human SLE may n and polyclonal Igsub pro-differ from that in murine models of SLE. Since humans are slation, (f) IgG antiTrT genetically heterogeneous, in contrast to the inbred mouse production of SLE CD5-B strains that develop lupus-like disease, the possibility exists that the pathogenesis of human SLE is also heterogeneous and varies among patients with otherwise similar clinical syndromes. Regardless of the precise explanation, the results rule out the notion that CD5+ B cells are the sole source of anti-DNA antibody in human SLE.
These results not only suggest the existence of two anti-DNA antibody producing B cell subsets in SLE but also raise the possibility that these subsets have different induction mechanisms. Thus, the levels of anti-DNA antibody secretion by CD5-B cells correlated closely with the level of polyclonal Ig production by the same subpopulation. In contrast, anti-DNA production by CD5+ B cells was independent of polyclonal Ig secretion by either this subpopulation or CD5-B cells (Fig. 7, a and c and data not shown) . We interpret these findings to suggest that a polyclonal stimulus is responsible for the production of anti-DNA antibody by CD5-B cells, whereas a more selective stimulus is responsible for anti-DNA production by CD5+ B cells. Although a recent study of CD5+ B cells in NZB/NZW F1 mice has suggested that these cells may be subject to antigen-induced clonal selection (47) , the stimulus responsible for the preferential activation of anti-DNA secreting CD5+ B cells in human SLE is unknown. Ifthe repertoire of CD5+ B cells is highly restricted, the same polyclonal stimulus could conceivably be responsible for the activation of CD5+ as well as CD5-B cells.
The underlying stimulus responsible for autoantibody production in SLE has been debated for many years. One model to account for autoantibody generation suggests that self-specific antibodies are encoded by germ line V gene repertoire (48) and are thus present in both normal and diseased individuals. In normal individuals, self-reactive cells are suppressed, but in disease, an abnormal polyclonal B cell activation may occur resulting in the pathological secretion of autoantibodies (24, (49) (50) (51) . This model predicts that autoantibodies would resemble those derived after polyclonal activation of normal B cells. A second model invokes self-antigens, not polyclonal activation, as the driving force for the production of autoantibodies (14, (52) (53) (54) . This antigen driven model predicts that autoantibodies would resemble antibodies produced during the secondary immune response to foreign antigens; these are usually derived from clonally related precursors, somatically mutated (often reflecting selection of mutations by antigens), and isotype switched (55, 56) .
It is possible that both antigen specific and polyclonal B cell activation contribute independently to the hypergammaglobulinemia and autoantibody production found in SLE patients. Alternatively, the presence of a factor capable of inducing polyclonal B cell activation in conjunction with low levels of antigen (or autoantigen) could induce the preferential proliferation of B cells reactive with that antigen. The current study suggests that polyclonal activation of B cells and preferential activation ofautoantibody producing clones are not mutually exclusive; rather, both mechanisms may contribute to the formation of anti-DNA antibody in SLE patients. A similar combined model of autoimmunity was proposed recently by Dziarski and Klinman et al. (57, 58) .
Recent studies suggest that autoantibodies, such as rheumatoid factor and anti-DNA antibody, differ from one another in their affinity for antigen depending on the Ig V genes that encode them. Some rheumatoid factors, for example, are cross-reactive low affinity autoantibodies encoded by germ line V genes (32, 57) , while others are of high affinity, harbor numerous somatic mutations and resemble antibodies elicited by exogenous antigens after secondary immunization (59) (60) (61) . In this regard, it will be of interest to determine whether the anti-DNA antibodies produced by CD5+ and CD5-B cells differ in affinity and/or V gene usage. Ofcourse, it will be of no less importance to determine the possible contribution of anti-DNA antibody produced by CD5+ and CD5-B cells to the clinical manifestation of SLE.
